Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the
Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for …

Alzheimer's disease (AD) is a degenerative neurological disease in elderly individuals.
Subjective cognitive decline (SCD), mild cognitive impairment (MCI) and further …

Despite all scientific efforts and many protracted and expensive clinical trials, no new drug
has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed …

Abstract The original Human Connectome Project yielded a rich data set on structural and
functional connectivity in a large sample of healthy young adults using improved methods of …

Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …

Alzheimer's disease is increasingly considered a large-scale network disconnection
syndrome, associated with progressive aggregation of pathological proteins, cortical …

Novel neuroimaging techniques that can sensitivity characterize healthy brain aging and
detect subtle neuropathologies have enormous potential to assist in the early detection of …

Sensitive and specific antemortem biomarkers of neurodegenerative disease and dementia
are crucial to the pursuit of effective treatments, required both to reliably identify disease and …

Background The hippocampus and hippocampal subfields have been found to be diversely
affected in Alzheimer's Disease (AD) and early stages of Alzheimer's disease by …

Mild cognitive impairment (MCI) is characterized by a level of cognitive impairment that is
lower than normal for a person's age, but a higher function than that that observed in a …